» Articles » PMID: 20230427

Serum Osteoprotegerin Levels and Long-term Prognosis in Subjects with Stable Coronary Artery Disease

Overview
Publisher Elsevier
Specialty Hematology
Date 2010 Mar 17
PMID 20230427
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Osteoprotegerin (OPG) is a secretory glycoprotein which belongs to the tumor necrosis factor receptor family. OPG immunoreactivity was demonstrated in normal blood vessels and in early atherosclerotic lesions. In a previous study, we showed that high serum OPG levels are associated with progression of coronary artery disease (CAD).

Objectives: The present study was designed to assess the association between serum OPG level and long-term prognosis in patients with stable coronary artery disease.

Methods: We performed a prospective, observational cohort study in 225 subjects to examine whether serum OPG levels can predict cardiovascular mortality. The median OPG levels were 1.02 ng mL(-1) at baseline.

Results: During the follow-up (61 + or - 25 months), 27 deaths occurred including 13 cardiovascular deaths. When the subjects were divided into three groups according to serum OPG level, the group with high serum OPG showed a higher risk for cardiovascular mortality. A Multivariate Cox proportional hazards model indicated that the higher risk of cardiovascular death in the high OPG level group remained significant (hazards ratio of 7.44, 95%CI 0.92-60.30, highest vs. lowest OPG tertile). In contrast, serum OPG levels were not associated with non-cardiovascular mortality.

Conclusions: Our data show that serum OPG levels are an independent predictor of cardiovascular mortality in patients with stable coronary artery disease.

Citing Articles

Circulating osteoprotegerin levels and cardiovascular outcomes in patients with pre-dialysis chronic kidney disease: results from the KNOW-CKD study.

Suh S, Oh T, Choi H, Kim C, Bae E, Ma S Sci Rep. 2024; 14(1):4136.

PMID: 38374135 PMC: 10876961. DOI: 10.1038/s41598-024-54335-y.


Plasma osteoprotegerin predicts adverse cardiovascular events in stable coronary artery disease: the PEACE trial.

Ma T, Zhao J, Yan Y, Liu J, Zang J, Zhang Y Front Cardiovasc Med. 2023; 10:1178153.

PMID: 37388640 PMC: 10300416. DOI: 10.3389/fcvm.2023.1178153.


Association between Serum Osteoprotegerin Levels and Severity of Coronary Artery Disease in Patients with Acute Myocardial Infarction.

Cottin Y, Issa R, Benalia M, Mouhat B, Meloux A, Tribouillard L J Clin Med. 2021; 10(19).

PMID: 34640343 PMC: 8509596. DOI: 10.3390/jcm10194326.


Disruption of Osteoprotegerin has complex effects on medial destruction and adventitial fibrosis during mouse abdominal aortic aneurysm formation.

Bumdelger B, Otani M, Karasaki K, Sakai C, Ishida M, Kokubo H PLoS One. 2020; 15(7):e0235553.

PMID: 32614927 PMC: 7331998. DOI: 10.1371/journal.pone.0235553.


TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?.

Bernardi S, Voltan R, Rimondi E, Melloni E, Milani D, Cervellati C Clin Sci (Lond). 2019; 133(10):1145-1166.

PMID: 31097613 PMC: 6526163. DOI: 10.1042/CS20181116.